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Transdermal Tulobuterol Patch,
a Long-Actingβ2-Agonist
Gen Tamura1, Masakazu Ichinose2, Yoshinosuke Fukuchi3 and Terumasa Miyamoto4
ABSTRACT
Tulobuterol patch (HokunalinTM Tape), which contains a β2-adrenergic agonist, is the first bronchodilator to be
available as a transdermal patch. This drug delivery system ensures that the time at which the peak drug con-
centration in the blood is reached coincides with the morning dip in respiratory function. The use of the patch
also prevents excessive increase in blood drug concentrations, thereby reducing the incidence of systemic ad-
verse reactions. Since 1998, when it was first approved in Japan and worldwide, the tulobuterol patch has been
used widely in the treatment of bronchial asthma and chronic obstructive pulmonary disease (COPD), and evi-
dence collected since it was approved has confirmed its clinical efficacy and safety. Because the patch is easy
to use and requires only once-daily application, treatment adherence of patients using the patch is good. In this
article, we discuss the rationale behind the development of the tulobuterol patch, evaluate data on its clinical ef-
ficacy and safety in the treatment of asthma and COPD, and examine the treatment adherence in individuals
using the patch.
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INTRODUCTION
The branded tulobuterol patch (HokunalinTM Tape)
is the first transdermal delivery system developed for
a β2-adrenergic agonist. It has been used extensively
in the long-term management of asthma and chronic
obstructive pulmonary disease (COPD) in Japan, Ko-
rea, and China. Its clinical efficacy and safety have
been established in clinical practice over the 13 years
since its launch in Japan in 1998. In addition, the
patch has attracted attention in recent years after pa-
tients using it were reported to exhibit significant im-
provement in their quality of life (QOL) and excellent
treatment adherence, which is important in the treat-
ment of chronic diseases. The present review de-
scribes the properties of the tulobuterol patch formu-
lation and outlines the clinical results obtained with
its use in the treatment of asthma and COPD.
To prepare this review, we conducted a literature
search using PubMed. The database was searched
using the terms “tulobuterol patch” and “tulobuterol”
for articles published since 1998, these searches
yielded 24 articles and 106 articles, respectively.
Among them, English-language articles describing
clinical trials of the patch and those supporting its
clinical efficacy were selected and reviewed.
FORMULATION PROPERTIES
BRANDED PREPARATION
The branded tulobuterol patch is the first success-
fully introduced transdermal delivery system for a
bronchodilator. The physiological functions and ac-
tivities of living beings follow circadian rhythms. Res-
piratory functions are known to be most severely sup-
pressed from late night until early in the morning.1
This, so-called “morning dip,” is known to be associ-
ated with the development of asthma attacks in the
early morning. Dethlefsen et al.2 investigated approxi-
mately 3000 untreated asthma patients to determine
the time of the day which asthma attacks are most
frequent, and reported that the attacks occurred in
clusters at around 4:00 am. Therefore, suppression of
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Fig.　1　Development concept of the tulobuterol patch.
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Fig.　2　The crystal reservoir system.
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this morning dip can be expected to bring about an
improvement in the patient’s QOL and also reduce
the burden on the caregiver in cases of childhood
asthma. The branded formulation was designed in ac-
cordance with the concept of chronotherapy: the
blood drug concentration is controlled in such a man-
ner that it is the highest during early morning, when
the respiratory functions are most severely sup-
pressed. This controlled release helps to reduce the
systemic adverse reactions associated with excessive
drug concentrations in the blood (Fig. 1). Long-acting
β2-agonists (LABA), such as salmeterol and for-
moterol, provide sustained action for 12 h by virtue of
their molecular structures. Similarly, for sustained-
release theophylline, which is administered orally,
the release of the active substance is controlled to
prolong the duration of its action. On the other hand,
the tulobuterol patch employs a technology that pro-
longs the duration of the drug’s action to 24 h. This
technology is the crystal reservoir system, which has
been patented for the patch.
THE CRYSTAL RESERVOIR SYSTEM
The crystal reservoir system, which is described be-
low, was developed with a view to reduce the size of
the formulation and prolonging the release of the
drug from a simple structure (Fig. 2). The plaster
body contains dissolved tulobuterol molecules and tu-
lobuterol crystals, which are dispersed homogene-
ously in the plaster body and transferred directly to
the skin when the tape is applied. The drug dissolves
and is dispersed from the crystals to compensate for
the reduction in the number of tulobuterol molecules
in the plaster body, thereby maintaining the concen-
tration of the drug substance dissolved in the plaster
body at a constant level and ensuring sustained re-
lease of the drug. This method of achieving sustained
release of the active substance via a transdermal
chrono-delivery system is based on the concept of
Tulobuterol Patch
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Fig.　3　Blood concentration curves after the application of the tulobuterol patch (2 mg in healthy adults and 1 
mg or 2 mg in pediatric patients) and administration of the tulobuterol tablet (1 mg) .
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DIFFERENCES BETWEEN BRANDED AND GE-
NERIC PREPARATIONS OF TULOBUTEROL
A generic preparation of the tulobuterol patch not us-
ing the crystal reservoir system employed for the
preparation of the branded formulation was recently
launched in the market. Yoshihara et al.3 compared
the skin permeation profiles between branded and
generic tulobuterol patches using normal skin and
corneum-removed skin of the rat. Their study
showed that skin permeability of the branded prepa-
ration was not significantly different between normal
skin and corneum-removed skin; however, the skin
permeability of the generic preparation was signifi-
cantly higher with corneum-removed skin than with
normal skin. Tojo et al.4 also conducted an in vitro
study using nude mouse skin and found that the skin
permeability of corneum-removed skin was signifi-
cantly higher than that of normal skin with the ge-
neric preparation of the drug, whereas, for the
branded preparation of the drug, the skin permeabil-
ity was similar for both skin samples. Thus, there are
differences in the formulation properties of the
branded and generic preparations. In patients who
have both childhood asthma and atopic dermatitis the
generic preparation should be used with caution, with
special attention being paid to the potential differ-
ences in the skin permeability of the drug between
normal and atopic skin.
CLINICAL EXPERIENCE
PHARMACOKINETICS
Blood concentration curves obtained after the appli-
cation of the tulobuterol patch (2 mg) and administra-
tion of the tulobuterol tablet (1 mg) in healthy adults
are shown in Figure 3. There was no excessive in-
crease in the blood drug concentration with the tu-
lobuterol patch, and the effective blood concentration
was maintained over a longer period with the tu-
lobuterol patch than with the tablet. As evident from
the figure, an ideal time-course for the increase in the
blood drug concentrations was observed after applica-
tion of the patch. The time to attainment of the maxi-
mum blood concentration was 9-12 h, and the effec-
tive blood concentration was maintained for 24 h after
once-daily application of the patch. Therefore, when
the patch is applied at bedtime, the maximum blood
concentration is achieved during early morning,
thereby suppressing asthmatic attacks occurring at
that time of the morning dip in respiratory function.
As shown in Figure 3, a similar blood concentration
curve was obtained when a 1 or 2 mg patch was ap-
plied to children.5 The branded tulobuterol patch,
which produces clinically significant improvement in
the peak expiratory flow (PEF) with minimal adverse
reactions, is therefore very useful in patients with
childhood asthma.
CLINICAL EFFECTS OF THE BRANDED TU-
LOBUTEROL PATCH IN ADULTS WITH BRON-
CHIAL ASTHMA
According to the Japanese Guideline for Prevention
and Management of Asthma, inhaled corticosteroids
(ICS) are the first choice of drugs for the long-term
management of bronchial asthma. β2-agonists are the
strongest bronchodilators among the standard drugs
used to treat bronchial asthma. The combination of
ICS and a long-acting β2-agonist (LABA) is therefore
recommended for the management of asthma from
Step 2 onward. In our multicenter, double-blind,
parallel-group study,6 239 adult patients with bron-
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Fig.　4　Increase in the morning PEF values after treatment with 1 mg or 2 
mg tulobuterol patch. **p < 0.01, †p < 0.05.
2 mg
**
†
†
† †
**
**
**
**
**
****
1 mg
(L/min)
Baseline Week 1 Week 2 Week 3 Week 4
40
30
20
10
0
chial asthma under treatment with ICS were random-
ized to receive tulobuterol patch at either 1 mgday
or 2 mgday, and the efficacy and safety of the patch
were investigated. In both groups, significant incre-
ments of the mean PEF values from baseline values
were observed, with the increase in the 2 mgday
group being significantly higher than that in the 1
mgday group (Fig. 4). There was no significant dif-
ference in the incidence of adverse reactions between
the two groups. Thus, the patch is included as a
LABA in the above-mentioned Japanese Guidelines
for the treatment of asthma, because its therapeutic
effect persists for over 24 hours after once-daily appli-
cation, and it has an additive effect when combined
with an ICS in patients with bronchial asthma.5-10
When ICS alone appears to be inadequate for the
long-term management of asthma, the addition of a
LABA, slow-release theophylline (SRT), or leukot-
riene receptor antagonist (LTRA) is considered more
beneficial than doubling of the dose of the ICS. Ho-
zawa et al.9 investigated which of these drugs is the
most desirable for combining with the ICS in the
long-term management of bronchial asthma. Sixty-
five asthma patients being treated with ICS alone
were randomized to receive the tulobuterol patch,
SRT, pranlukast (LTRA), or ICS alone (control), and
the changes in the respiratory parameters in each
group were compared. The improvement in the PEF
tended to be the highest for the patch. That is, the re-
sults suggested that the addition of the tulobuterol
patch to an ICS was the most effective strategy for
the long-term management of asthma. A long-
standing issue of concern in the treatment of bron-
chial asthma has been the emergence of tolerance,
that is, a reduction in the bronchodilatory effect of a
short-acting β2-agonist after frequent and repeated
use. Kume et al.7 reported that long-term use of the
tulobuterol patch was not associated with any de-
crease in the drug susceptibility of adrenergic β2-
receptors in the airway smooth muscle; this indicates
that the use of the tulobuterol patch did not lead to
tolerance. In addition, Horiguchi et al.8 reported that
no signs of tachyphylaxis were found even after year-
long use of the tulobuterol patch. A number of stud-
ies11-13 have compared the tulobuterol patch with sal-
meterol. Fujimoto et al.11 treated 54 asthma patients
with PEF variations or symptoms despite ICS treat-
ment with increasing dose, addition of salmeterol, or
addition of tulobuterol, and assessed respiratory func-
tions and QOL (the Asthma Quality of Life Question-
naire). Although the assessment of airway reversibil-
ity was not included in the patient background data, a
significant improvement was noted at the 8th week
only in patients treated with ICS and salmeterol. Ko-
bayashi et al.12 added tulobuterol tape and then re-
placed it with salmeterol in 64 patients receiving a
dose of 200 to 800 μgday of ICS for at least 3
months. These authors observed greater improve-
ment of PEF when salmeterol was administered.
However, the possibility of an order effect cannot be
ruled out. A study with the drugs administered in the
reverse order is required to clarify this. Nishiyama et
al.13 assigned 54 patients with moderate to severe
asthma not responding well to a low dose of ICS to
two groups―one receiving salmeterol and the other,
tulobuterol―and assessed respiratory functions and
QOL (the St. George’s Hospital Respiratory Question-
naire, SGRQ). They found that both groups showed
improvement in respiratory functions and QOL, indi-
cating that the tulobuterol patch is a useful bron-
chodilator for combining with ICS. Thus, clinical
studies where the use of adequate inhalation tech-
niques is guaranteed, the tulobuterol patch may be
less effective than salmeterol with respect to improve-
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ments in respiratory functions. However, the patch is
a useful LABA for combining with ICS in actual clini-
cal practice, and its efficacy and safety are equivalent
to those of salmeterol.
CLINICAL EFFECTS OF THE BRANDED TU-
LOBUTEROL PATCH IN CHILDREN WITH BRON-
CHIAL ASTHMA
The combined use of the tulobuterol patch and an
ICS has also been reported to be effective in the treat-
ment of bronchial asthma in children. In addition, the
tulobuterol patch has the advantage of being highly
convenient to use in children of all ages. Yoshihara et
al.14 conducted a randomized, parallel-group, com-
parative study in 10 pediatric patients with severe
asthma who were under ICS treatment. They demon-
strated that the tulobuterol patch (once-daily applica-
tion) showed an add-on effect equivalent to that of in-
haled salmeterol (twice-daily inhalation). In addition,
they compared the effect of increasing the dose of the
ICS to that of adding the tulobuterol patch to the ICS
in 18 pediatric patients with severe asthma and found
that the latter strategy resulted in a significantly
greater improvement in the PEF values and a signifi-
cantly higher percentage of respiratory symptom-free
days than the former. These results showed that the
tulobuterol patch is also useful for the long-term man-
agement of asthma in the pediatric population. Thus,
the tulobuterol patch appears to be suitable for the
treatment of asthma in almost all age groups, from in-
fants aged 6 months to the elderly, and the com-
bined application of this patch with an ICS plays an
important role in the long-term management of
asthma.
CLINICAL EFFECTS OF THE BRANDED TU-
LOBUTEROL PATCH IN PATIENTS WITH STA-
BLE COPD
According to the current Japanese Guidelines for the
diagnosis and treatment of COPD, the drug of first
choice for the pharmacotherapy of stable COPD is a
long-acting anticholinergic agent or LABA. However,
because COPD treatment has to be continued for a
prolonged period, drugs having not only high efficacy
and safety but also a good compliance rate are desir-
able in the treatment of COPD. An inhaled bron-
chodilator is directly administered into the airways
and is regarded as a desirable dosage form, in view of
its efficacy and safety. However, inhalation of a suffi-
cient dosage may be difficult in some COPD patients
because of compromised respiratory functions. Even
in patients who have difficulty in learning the inhala-
tion technique, the tulobuterol patch is easy to use. In
addition, the patch has the advantage that it can be
removed at any time, for example, in the event of ad-
verse reactions.
COMPARISON OF THE BRANDED TULOBU-
TEROL PATCH AND SLOW-RELEASE THEO-
PHYLLINE
Minami et al.15 conducted a randomized controlled
study of the tulobuterol patch and SRT in 16 patients
with moderate to severe COPD. They reported a sig-
nificantly greater improvement in subjective symp-
toms and the QOL in the tulobuterol patch group
than in the SRT group. Evaluation of the number of
expectorations, ability to expectorate, wheezing
score, cough score, and the “Total,” “Impact,” and
“Symptoms” scores in the SGRQ revealed a signifi-
cantly greater improvement in the tulobuterol patch
group than in the SRT group. The only adverse reac-
tion noted was increased volume of sputum in one
case in the tulobuterol patch group. Kanehara et al.16
compared theophylline and tulobuterol in 26 patients
with mild to moderate COPD, by using a crossover
design. These authors reported that, while only pa-
tients treated with theophylline showed improvement
in respiratory functions, an anti-inflammatory effect
on neutrophil inflammation was not observed with
either drug. However, six patients treated with theo-
phylline―five of whom developed adverse reactions
and one who cited personal reasons―dropped out of
the study, while all patients treated with tulobuterol
completed the study. Thus, clinical evaluation of this
study may be difficult.
THE BAREC STUDY: COMPARISON BETWEEN
THE BRANDED TULOBUTEROL PATCH AND IN-
HALED SALMETEROL
Fukuchi et al.17 conducted a multicenter, parallel-
group, comparative study (the BAREC study) of the
tulobuterol patch and inhaled salmeterol in 92 pa-
tients with stable COPD (GOLD stage II and III
phases). They reported improvements in the morn-
ing and evening PEF values in both groups, with no
significant intergroup difference (Fig. 5). However, a
significantly greater improvement of the SGRQ at 8
weeks after the start of treatment was observed in the
tulobuterol patch group compared with the sal-
meterol group (Fig. 6). In addition, treatment compli-
ance was also significantly better in the tulobuterol
patch group than in the salmeterol group. No serious
adverse reactions occurred in either group. These
findings show that, in terms of clinical efficacy, the tu-
lobuterol patch is equivalent or superior to inhaled
salmeterol and that it is useful in the long-term man-
agement of patients with stable COPD. Yamagata et
al.18 conducted a crossover comparative study of sal-
meterol and tulobuterol in 11 COPD patients. Their
study revealed that the forced expiratory volume in 1
second (FEV1) and forced vital capacity (FVC) were
significantly higher in the salmeterol group than in
the tulobuterol group. However, because the
sustained-release technology in tulobuterol is de-
signed such that the drug is effective for 24 h, a
Tamura G et al.
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Fig.　5　Improvement in the morning (A: left panel) and evening (B: right panel) PEF values over a 12-week treatment peri-
od with tulobuterol patch and inhaled salmeterol in patients with stable COPD.
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steady concentration of the drug is achieved after the
patch has been applied two or more times,19 there-
fore, the effect of a single dose may not have been
100%. On the other hand, we speculate that a suffi-
cient effect of salmeterol might have been obtained
24 h later because the second dose had been adminis-
tered within this period.
THE BAREC II STUDY: ADD-ON EFFECTS OF
THE TULOBUTEROL PATCH IN PATIENTS WHO
WERE TREATED WITH INHALED TIOTROPIUM
The Global Initiative for Chronic Obstructive Lung
Disease (GOLD)20 and the Japanese Guidelines rec-
ommend combining 2 or more drugs rather than in-
creasing the dose of a single drug when a single drug
fails to sufficiently alleviate the symptoms. This is be-
cause the use of multiple drugs with differing mecha-
nisms of action has shown better treatment outcomes
in COPD, without an increase in the frequency of ad-
verse reactions. Ichinose et al.21 conducted a multi-
center, parallel-group comparative study (the BAREC
II study) to evaluate the clinical effects and safety of a
combination of the tulobuterol patch and inhaled tiot-
ropium22 in patients with COPD. After a 2-week run-
in period, 103 patients with stable COPD were ran-
domized to receive either inhaled tiotropium alone
(Tio group) or both tulobuterol patch and inhaled
tiotropium (Tio + Tulo group). In both groups, the
FVC and FEV1 as well as the dyspnea improved sig-
nificantly after 8 weeks of treatment. A comparison of
both groups showed that the percent changes in the
inspiratory capacity (Fig. 7) and morning and evening
PEF values were significantly greater in the Tio +
Tulo group than in the Tio group (Fig. 8). In addition,
a significant improvement in the total SGRQ score
and improvements in the “Activity” and “Impact”
scores were observed only in the Tio + Tulo group
(Fig. 9). Adverse reactions suspected to be causally
related to the treatment included mild urticaria and
decreased mastication in one case in each groups;
moderate dysuria associated with elevated blood
pressure in one case in the Tio group; and mild head-
ache in one case of the Tio + Tulo group. In COPD
patients, addition of the tulobuterol patch to inhaled
tiotropium produced significant improvements in
dyspnea and SGRQ score, as well as in the pulmonary
function parameters. These benefits may be attribut-
able to a reduction in pulmonary hyperinflation re-
sulting from an improvement in the patency of the pe-
ripheral airways effected by tulobuterol entering the
systemic circulation. Akamatsu et al.23 divided 60
COPD patients into two groups―one treated with tu-
lobuterol alone or the other treated with a combina-
Tulobuterol Patch
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Fig.　7　Effect of the tulobuterol patch used in combination 
therapy on the percent change in inspiratory capacity. Each 
group was assessed for the percent change from baseline at 
week 8. *p < 0.05.
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Fig.　8　Effect of using the tulobuterol patch in combination therapy on morning (A: left panel) and evening (B: right panel) 
PEF values. *p < 0.05, **p < 0.01.
ΔP
E
F
 (
%
)
30
25
20
15
10
5
0
0 1 2 3 4
Week
5 6 87 0 1 2 3 4
Week
5 6 87
A
ΔP
E
F
 (
%
)
30
25
20
15
10
5
0
B
* *
* *
* **** *
*
Tio group
Tio + Tulo group
Tio group
Tio + Tulo group
Fig.　9　Effect of tulobuterol patch used in combination therapy on St 
George’s Respiratory Questionnaire. *p < 0.05, ***p < 0.001, †p < 0.05 
(Intergroup).
ΔS
G
R
Q
 (
un
its
)
0
-4
-8
-12
Tio group
Tio + Tulo group
Symptoms Activity Impact Total SGRQ
* ***
† †
***
tion of tulobuterol and tiotropium―and assess their
respiratory functions. The findings of this study sup-
ported those of the BAREC II study, confirming the
add-on effects of tulobuterol when combined with
tiotropium.
TREATMENT ADHERENCE
Treatment adherence is a very important factor in the
management of chronic diseases. Tamura and Ohta24
conducted a web-based survey on the treatment ad-
herence to drugs used in asthma and COPD patients
and collected the responses of 1470 individuals, in-
cluding patients with asthma or COPD and their par-
ents. The percentage of patients who took the pre-
scribed drug as instructed was 31.0-64.6% for inhaled
drugs and 84.0% for the tulobuterol patch; in other
words, treatment adherence to the tulobuterol patch
was significantly higher than that for any inhaled
drug (Fig. 10). In addition to the complexity of the in-
halation technique, the need for frequent administra-
Tamura G et al.
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Fig.　10　Adherence with regimens by indication. Q: Are you taking drugs currently prescribed for treatment of asthma/COPD 
as directed by your physicians? Please provide an answer for each drug. *p < 0.01.
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tion of an inhaled drug is another reason for the
lower treatment adherence to an inhaled drug. Fur-
ther, the percentage of individuals who preferred
once-daily administration was 83.2% (Fig. 11). Patient
adherence to the use of the tulobuterol patch is high
because of the ease of its application and the need for
only once-daily administration. The patch satisfies the
prerequisites of a drug for long-term management of
chronic respiratory diseases, such as asthma and
COPD. Sugawara et al.25 compared the treatment ad-
herence of salmeterol to that of tulobuterol in 26 pa-
tients with moderate to severe COPD using a cross-
over design. Among patients aged <80 y, adherence
to tulobuterol was found to be better than that to sal-
meterol, and a similar but more significant difference
was noted among those aged 80 y. The findings of
this study support the results reported by Tamura
and Ohta.
PERSPECTIVE AND CLINICAL INTERPRE-
TATION
CLASSIFICATION AS A LABA
Tulobuterol patch is a unique β2 adrenergic agonist
drug preparation that allows transdermal delivery of
tulobuterol through the crystal reservoir system,
thereby avoiding the decrease in respiratory func-
tions seen in asthma patients receiving other formula-
tions during the early morning hours (morning dip).
This is because the patch prevents excessive increase
in blood drug concentrations, while also reducing the
incidence of systemic adverse reactions. The effect of
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the drug after once-daily application persists for over
24 h, and the formulation is designed such that, once
the patch is applied at bedtime, the blood drug con-
centration reaches its peak in the early morning and
the therapeutic effect is sustained for a prolonged pe-
riod. The tulobuterol patch was found to exert an ad-
ditive effect when combined with ICS in bronchial
asthma patients,6 therefore, the patch is positioned as
a LABA in the Japanese Guidelines for Prevention
and Management of Asthma and in the Guidelines for
Diagnosis and Treatment of COPD. The synergistic
effects of ICS and LABAs are explained by the fact
that inhaled steroids increase the expression of β2
adrenergic receptors, while β2 adrenergic agonists
causes the down regulation of these receptors.26 On
the other hand, the β2 agonists activate the steroid re-
ceptors to potentiate the effect of the steroids.27 In ad-
dition, the tulobuterol patch may exert both local ef-
fects on the lungs and systemic effects. Yamaguchi et
al.28 investigated the effect of tulobuterol on the adhe-
sive forces between blood eosinophils and human
umbilical vein endothelial cells (HUVEC) in an in vi-
tro study. They reported that tulobuterol significantly
inhibited the adhesion between eosinophils and HU-
VECs activated by IL-4 + TNFα, IL-5, or formyl-
methionyl-leucyl-phenylalanine. Thus, tulobuterol can
decrease the adhesion of blood eosinophils to endo-
thelial cells. These findings imply that the tulobuterol
patch may possibly exert an anti-inflammatory effect.9
ROLE AS A THERAPEUTIC AGENT FOR COPD
Although COPD is recognized as an intractable dis-
ease, its treatment has advanced in recent times. It is
now accepted that early aggressive treatment, includ-
ing the use of long-acting bronchodilators, can im-
prove the prognosis of the disease. Treatment of
COPD has been focused not only on improving respi-
ratory functions but also on the patients’ QOL. In par-
ticular, because many COPD patients are elderly and
have problems such as difficulty mastering the tech-
nique of using inhalers and insufficient inhalation
rates, a different, more convenient route of admini-
stration may be useful for these patients. In the
BAREC study, the tulobuterol patch improved the
subjective symptoms and QOL, probably by relieving
the peripheral airway obstruction. Use of the tu-
lobuterol patch causes the drug to reach the periph-
eral airways through the systemic circulation after
transdermal absorption, thereby maintaining the
patency of the peripheral airways and resulting in
more effective expiration and reduction of the resid-
ual volume. This prevents pulmonary hyperinflation
and improves the exercise tolerance, which in turn
improves the patients’ QOL. Many studies have
shown that, pathologically, COPD involves mainly the
peripheral airways. Thus, the improvement in periph-
eral airway function may well be the reason for the
improvement in QOL brought about by the use of the
tulobuterol patch. In the BAREC II study, an add-on
effect of the tulobuterol patch was noted in patients
treated with inhaled tiotropium, and the difference
sites of action of these two drugs was speculated to
underlie this effect: tiotropium exerts its effects via
muscarinic M3 receptors, while tulobuterol acts via
the β2 adrenergic receptors. Because activated mus-
carinic M3 receptors are found mainly in the central
airways,29 tiotropium, an anticholinergic agent, may
mainly improve the functions of the central airways
rather than those of the peripheral airways. On the
other hand, tulobuterol may activate the β2 adrener-
gic receptors in the peripheral airways via the sys-
temic circulation; thus, the combination of the two
agents would be expected to have complementary ef-
fects and improve the functions of both the peripheral
and central airways.
PHARMACOLOGICAL STUDIES SUPPORTING
THE CLINICAL RESULTS
The results of pharmacological studies of the tu-
lobuterol patch support its clinical effects. One such
study demonstrated that tulobuterol promotes airway
ciliary movement, thereby enhancing airway clear-
ance.30 This effect may underlie the improvement of
expectoration and cough, which are the subjective
symptoms of COPD. COPD patients have low flat dia-
phragms, and the consequent decrease in the con-
tractility of the respiratory muscles may be associated
with decreased respiratory functions and subjective
symptoms in patients with COPD. Shindoh et al.31,32
reported the significance of the systemic effects of
the tulobuterol patch. They also found that the in-
creased contractility of the mouse diaphragmatic
muscle was maintained for 24 h after the application
of the tulobuterol patch and that the patch sup-
pressed the decrease in the contractility of the dia-
phragmatic muscle for 24 h observed in a mouse
model of endotoxin-induced sepsis. These findings
suggest that the tulobuterol patch may increase the
contractility of the weakened diaphragmatic muscle
in both asthma and COPD patients. Burioka et al.33
assessed the effects of tulobuterol on the expression
of the human clock gene Per1 mRNA and confirmed
that the drug does not affect its expression. This find-
ing implies that the administration of tulobuterol at
bedtime does not affect night sleep.
IMPORTANT PREREQUISITES OF THERAPEU-
TIC AGENTS FOR THE TREATMENT OF
CHRONIC RESPIRATORY DISEASES
Treatment adherence is very important in the man-
agement of patients with chronic respiratory dis-
eases. Although it has been established beyond
doubt that inhaled drugs play central roles in the
treatment of chronic respiratory diseases, such as
asthma and COPD, they are often associated with low
treatment adherence. Other problems contributing to
Tamura G et al.
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low patient adherence to inhaler therapy include diffi-
culty in mastering the technique for using inhalers
and insufficient inhalation rate. Because of the ease of
its application and the need for only once-daily ad-
ministration, the use of the tulobuterol patch is asso-
ciated with good treatment adherence. Consequently,
the preparation satisfies the prerequisites of a drug
for the long-term management of asthma and COPD.
In addition, in the treatment of chronic respiratory
diseases, it is important that long-term use of a drug
is not associated with reduced efficacy; that is, that no
tolerance is induced by its long-term use. Neither a
decrease in efficacy nor the development of tolerance
was observed with the use of the tulobuterol patch,
even after year-long use. Thus, the drug preparation
is considered suitable for use in the long-term man-
agement of chronic respiratory diseases, such as
asthma and COPD. Generic preparations of the tu-
lobuterol patch have recently been launched in the
market, but they lack the crystal reservoir technology
incorporated in the branded preparation. Some re-
ports3,4,34 indicate that tulobuterol is released within a
shorter time from the generic preparation than from
the branded preparation. Therefore, differences in
the properties of the two types of preparations should
be taken into consideration when using the tu-
lobuterol patch.
CONCLUSION
The tulobuterol patch is a unique transdermal deliv-
ery system prepared using crystal reservoir technol-
ogy. It has been shown to significantly contribute to
the pharmacotherapy of asthma by countering the
morning dip in respiratory function. Evidence indi-
cates that the drug reaches the peripheral airways via
the systemic circulation, is useful for the long-term
management of COPD, and improves the patients’
QOL. In addition, the tulobuterol patch is excellent in
terms of treatment adherence and convenience of use
because it requires only once-daily application. These
properties make this transdermal delivery patch suit-
able for the long-term management of chronic respi-
ratory diseases.
REFERENCES
1. Turner-Warwick M. On observing patterns of airflow ob-
struction in chronic asthma. Br J Dis Chest 1977;71:73-86.
2. Dethlefsen U, Repges R. Ein neues Therapieprinzip bei
nahtlichem Asthma. Klin Med 1985;80:44-7.
3. Yoshihara S, Fukuda H, Abe T, Arisaka O. Comparative
study of skin permeation profiles between brand and ge-
neric tulobuterol patches. Biol Pharm Bull 2010;33:1763-
5.
4. Tojo K, Hikima T. Bioequivalence of marketed transder-
mal delivery systems for tulobuterol. Biol Pharm Bull
2007;30:1576-9.
5. Iikura Y, Uchiyama H, Akimoto K et al. Pharmacokinetics
and pharmacodynamics of the tulobuterol patch, HN-078,
in childhood asthma. Ann Allergy Asthma Immunol 1995;
74:147-51.
6. Tamura G, Sano Y, Hirata K, Ishioka S, Nakashima M,
Miyamoto T. Effect of transdermal tulobuterol added to
inhaled corticosteroids in asthma patients. Allergol Int
2005;54:615-20.
7. Kume H, Kondo M, Ito Y, Suzuki R, Yamaki K, Takagi K.
Effects of sustained-release tulobuterol on asthma control
and β-adrenoceptor function. Clin Exp Pharmacol Physiol
2002;29:1076-83.
8. Horiguchi T, Kondo R, Miyazaki J, Fukumoto K, Torigoe
H. Clinical evaluation of a transdermal therapeutic system
of the β2-agonist tulobuterol in patients with mild or mod-
erate persistent bronchial asthma. Arzneimittelforschung
2004;54:280-5.
9. Hozawa S, Haruta Y, Terada M, Yamakido M. Effects of
the addition of β2-agonist tulobuterol patches to inhaled
corticosteroid in patients with asthma. Allergol Int 2009;
58:509-18.
10. Burioka N, Miyata M, Endo M et al. Alteration of the cir-
cadian rhythm in peak expiratory flow of nocturnal
asthma following nighttime transdermal beta 2-
adrenoceptor agonist tulobuterol chronotherapy. Chrono-
biol Int 2005;22:383-90.
11. Fujimoto K, Komatsu Y, Yasuo M, Urushihata K, Kubo K.
Comparison of the clinical efficacy of salmeterol and
sustained-release tulobuterol (patch) on inadequately
controlled asthma patients on inhaled corticosteroids. J
Asthma 2006;43:501-7.
12. Kobayashi Y, Yasuba H, Kudou M, Kita H. Addition of
transdermal or inhaled long-acting Beta2-agonists in adult
asthmatic patients treated with inhaled corticosteroids:
switchover study from tulobuterol patch to salmeterol dry
powder inhaler. J Asthma 2007;44:77-81.
13. Nishiyama O, Taniguchi H, Kondoh Y et al. Comparison
of the effects of tulobuterol patch and salmeterol in mod-
erate to severe asthma. Clin Exp Pharmacol Physiol 2006;
33:1016-21.
14. Yoshihara S, Yamada Y, Abe T, Arisaka O. The use of
patch formulation of tulobuterol, a long-acting β2-
adrenoreceptor agonist, in the treatment of severe pediat-
ric asthma. Ann Allergy Asthma Immunol 2006;96:879-80.
15. Minami S, Kawayama T, Ichiki M et al. Clinical efficacy of
the transdermal tulobuterol patch in patients with chronic
obstructive pulmonary disease: a comparison with slow-
release theophylline. Intern Med 2008;47:503-9.
16. Kanehara M, Yokoyama A, Tomoda Y et al. Anti-
inflammatory effects and clinical efficacy of theophylline
and tulobuterol in mild-to-moderate chronic obstructive
pulmonary disease. Pulm Pharmacol Ther 2008;21:874-8.
17. Fukuchi Y, Nagai A, Seyama K et al. Clinical efficacy and
safety of transdermal tulobuterol in the treatment of sta-
ble COPD: an open-label comparison with inhaled sal-
meterol. Treat Respir Med 2005;4:447-55.
18. Yamagata T, Hirano T, Sugiura H et al. Comparison of
bronchodilatory properties of transdermal and inhaled
long-acting beta 2-agonists. Pulm Pharmacol Ther 2008;
21:160-5.
19. Uematsu T, Nakano M, Kosuge K, Kanamaru M, Naka-
shima M. The pharmacokinetics of the β2-adrenoceptor
agonist, tulobuterol, given transdermally and by inhala-
tion. Eur J Clin Pharmacol 1993;44:361-4.
20. Global Initiative for Chronic Obstructive Lung Disease
(GOLD). Global Strategy for Diagnosis, Management,
and Prevention of Chronic Obstructive Pulmonary Dis-
ease. Available at: http:www.goldcopd.org.
21. Ichinose M, Seyama K, Nishimura M et al. Additive ef-
Tulobuterol Patch
Allergology International Vol 61, No2, 2012 www.jsaweb.jp 229
fects of transdermal tulobuterol to inhaled tiotropium in
patients with COPD. Respir Med 2010;104:267-74.
22. Tashkin DP, Celli B, Senn S et al. A 4-year trial of tiotro-
pium in chronic obstructive pulmonary disease. N Engl J
Med 2008;359:1543-54.
23. Akamatsu K, Yamagata T, Takahashi T et al. Improve-
ment of pulmonary function and dyspnea by tiotropium in
COPD patients using a transdermal beta (2)-agonist.
Pulm Pharmacol Ther 2007;20:701-7.
24. Tamura G, Ohta K. Adherence to treatment by patients
with asthma or COPD: comparison between inhaled
drugs and transdermal patch. Respir Med 2007;101:1895-
902.
25. Sugawara T, Nanjo Y, Yamazaki M et al. Comparison of
adherence and efficacy between inhaled salmeterol and
transdermal tulobuterol patch in elderly patients with
chronic obstructive pulmonary disorder. J Am Geriatr Soc
2009;57:919-20.
26. Mak JC, Nishikawa M, Barnes PJ. Glucocorticosteroids
increase β2-adrenergic receptor transcription in human
lung. Am J Physiol 1995;268:L41-6.
27. Eickelberg O, Roth M, Lorx R et al. Ligand-independent
activation of the glucocorticoid receptor by β2-adrenergic
receptor agonists in primary human lung fibroblasts and
vascular smooth muscle cells. J Biol Chem 1999;274:
1005-10.
28. Yamaguchi T, Nagata M, Miyazawa H et al. Tulobuterol, a
β2-agonist, attenuates eosinophil adhesion to endothelial
cells. Allergol Int 2005;54:283-8.
29. Barnes PJ. Neural control of human airways in health and
disease. Am Rev Respir Dis 1986;134:1289-314.
30. Matthys H, Daikeler G, Krauss B, Vastag E. Action of tu-
lobuterol and fenoterol on the mucociliary clearance. Res-
piration 1987;51:105-12.
31. Shindoh C, Tsushima R, Shindoh Y, Tamura G. Transder-
mal treatment with tulobuterol increases isometric con-
tractile properties of diaphragm muscle in mice. Tohoku J
Exp Med 2007;212:309-17.
32. Shindoh C, Murakami Y, Shishido R, Sasaki K, Nishio T,
Miura M. Tulobuterol patch maintains diaphragm muscle
contractility for over twenty-four hours in a mouse model
of sepsis. Tohoku J Exp Med 2009;218:271-8.
33. Burioka N, Takata M, Endo M et al. Treatment with
beta2-adrenoceptor agonist in vivo induces human clock
gene, Per1, mRNA expression in peripheral blood. Chron-
obiol Int 2007;24:183-9.
34. Naruto I, Kitano A, Matsuyama K et al. [A comparison
study between the brand and generic tulobuterol
patches]. [Jpn J Med Pharm Sci] 2006;56:727-34(in Japa-
nese).
